ライフサイエンスコーパス: ventricular tachyarrhythmia

1 s resuscitated cardiac arrest or spontaneous ventricular tachyarrhythmia).

2 ned by a low ejection fraction and inducible ventricular tachyarrhythmia.

3 uring the year before their index episode of ventricular tachyarrhythmia.

4 ing which atrial shock delivery may induce a ventricular tachyarrhythmia.

5 ally contributes to RyR2 hyperactivation and ventricular tachyarrhythmia.

6 ciated with a higher likelihood of malignant ventricular tachyarrhythmia.

7 ion and hospitalization for heart failure or ventricular tachyarrhythmia.

8 type 2 (LQT2) and are associated with fatal ventricular tachyarrhythmia.

9 y end point was an ICD shock for adjudicated ventricular tachyarrhythmia.

10 de configuration to treat potentially lethal ventricular tachyarrhythmia.

11 d increase vulnerability to life-threatening ventricular tachyarrhythmia.

12 h or appropriate ICD discharge for sustained ventricular tachyarrhythmia.

13 ed all 12 episodes of spontaneous, sustained ventricular tachyarrhythmia.

14 ed all 12 episodes of spontaneous, sustained ventricular tachyarrhythmia.

15 CM patients with increased susceptibility to ventricular tachyarrhythmias.

16 ands-off periods for shock delivery to treat ventricular tachyarrhythmias.

17 susceptibility to spontaneous and inducible ventricular tachyarrhythmias.

18 uctural heart disease are at higher risk for ventricular tachyarrhythmias.

19 have AP and QT prolongation, and spontaneous ventricular tachyarrhythmias.

20 ased risk of syncope and sudden death due to ventricular tachyarrhythmias.

21 ived 701 antiarrhythmic device therapies for ventricular tachyarrhythmias.

22 no O-CKO mice were inducible into sustained ventricular tachyarrhythmias.

23 an increased risk of sudden death caused by ventricular tachyarrhythmias.

24 suppressing alternans and thereby preventing ventricular tachyarrhythmias.

25 thologic phenotype of ischemiainduced lethal ventricular tachyarrhythmias.

26 and rescued transgenic hearts from malignant ventricular tachyarrhythmias.

27 his impact of AF in patients presenting with ventricular tachyarrhythmias.

28 tients receiving a dual-chamber ICD to treat ventricular tachyarrhythmias.

29 sed in the treatment of supraventricular and ventricular tachyarrhythmias.

30 e therapy for management of life-threatening ventricular tachyarrhythmias.

31 extensively used for the acute treatment of ventricular tachyarrhythmias.

32 Recurrent syncope was always associated with ventricular tachyarrhythmias.

33 acterized clinically by an increased risk of ventricular tachyarrhythmias.

34 arization and syncope or sudden death due to ventricular tachyarrhythmias.

35 TS) and may presage the onset of polymorphic ventricular tachyarrhythmias.

36 f aborted sudden cardiac death or refractory ventricular tachyarrhythmias.

37 changes did not correlate with a history of ventricular tachyarrhythmias.

38 ncing the electrophysiological substrate for ventricular tachyarrhythmias.

39 echocardiographic risk factors in predicting ventricular tachyarrhythmias.

40 s (p < 0.005) were independent predictors of ventricular tachyarrhythmias.

41 ined as appropriate ICD therapy or sustained ventricular tachyarrhythmias.

42 nal ablation for the prevention of recurrent ventricular tachyarrhythmias.

43 ring seizures and are resistant to inducible ventricular tachyarrhythmias.

44 lities of electrical activation that promote ventricular tachyarrhythmias.

45 ts with coronary artery disease and unstable ventricular tachyarrhythmias.

46 region, which may promote susceptibility to ventricular tachyarrhythmias.

47 s cardiac events, including life-threatening ventricular tachyarrhythmias.

48 l-cause mortality and appropriate shocks for ventricular tachyarrhythmias.

49 appropriate ICD shock defined as a shock for ventricular tachyarrhythmias.

50 with dilated cardiomyopathy at risk of fatal ventricular tachyarrhythmias.

51 transplantation but continuing proneness to ventricular tachyarrhythmias.

52 between post-CRT-D LVEF and ICD therapy for ventricular tachyarrhythmias.

53 isk of sudden death previously attributed to ventricular tachyarrhythmias.

54 th in patients presenting consecutively with ventricular tachyarrhythmias.

55 ilated cardiomyopathy, as well as atrial and ventricular tachyarrhythmias.

56 e progression and a reduction in the risk of ventricular tachyarrhythmias.

57 posite end point (n=22 patients; 19 atrial/2 ventricular tachyarrhythmia, 1 death) included RV LGE pr

58 , the proportions of patients with sustained ventricular tachyarrhythmia (39.7% versus 48.2%; P=0.050

59 linical entities comprising these idiopathic ventricular tachyarrhythmias, a few well-defined clinica

60 ls in escape rhythms and bradycardia-related ventricular tachyarrhythmias after AVB in mice.

61 es the incidence, frequency, and duration of ventricular tachyarrhythmias after coronary artery occlu

62 nt reduction in the risk of life-threatening ventricular tachyarrhythmias among patients with NICM.

63 apy will reduce the risk of life-threatening ventricular tachyarrhythmias among patients with nonisch

64 ent of 702 patients with inducible sustained ventricular tachyarrhythmia and 35% of 1394 patients wit

65 Secondary outcomes included sustained ventricular tachyarrhythmia and appropriate ICD therapy.

66 enced 21 episodes, with correct detection of ventricular tachyarrhythmia and subsequent shock therapy

67 occurred in 98 patients, representing 32% of ventricular tachyarrhythmias and 76% of those that would

68 mall case series of patients with refractory ventricular tachyarrhythmias and cardiomyopathy.

69 by speckle-tracking echocardiography predict ventricular tachyarrhythmias and provide incremental pro

70 ignificantly suppressed electrically induced ventricular tachyarrhythmias and reduced the incidence o

71 dromes, sympathetic stimulation precipitates ventricular tachyarrhythmias and sudden cardiac death ex

72 Ventricular tachyarrhythmias and sudden cardiac death sh

73 tation in heart failure have been plagued by ventricular tachyarrhythmias and sudden cardiac death.

74 a genetic disease associated with a risk of ventricular tachyarrhythmias and sudden death, especiall

75 neity that predisposes to the development of ventricular tachyarrhythmias and sudden death.

76 tations in this gene cause susceptibility to ventricular tachyarrhythmias and sudden death.

77 nates in mediating sympathoexcitation during ventricular tachyarrhythmias and that cardiopulmonary ba

78 th neonatal sudden death and, in some cases, ventricular tachyarrhythmias and waxing and waning cardi

79 es of advanced conduction disease, malignant ventricular tachyarrhythmias, and advanced heart failure

80 eases the occurrence of atrial fibrillation, ventricular tachyarrhythmias, and stroke and length of s

81 duce the incidence of myocardial infarction, ventricular tachyarrhythmias, and sudden cardiac death d

82 ur understanding and treatment of idiopathic ventricular tachyarrhythmias, and these advances are the

83 syncope of undetermined origin and inducible ventricular tachyarrhythmias, appropriate implantable ca

84 Ventricular tachyarrhythmias are characteristic of giant

85 Polymorphic ventricular tachyarrhythmias are highly lethal arrhythmi

86 ity (<5% that of human heart), and malignant ventricular tachyarrhythmias are infrequent during acute

87 ent a minority of cardiovascular deaths, and ventricular tachyarrhythmias are mainly associated with

88 13 (41%) received appropriate therapy for a ventricular tachyarrhythmia at least once in the six-mon

89 gistry demonstrates a high rate of sustained ventricular tachyarrhythmias at 3 months in at-risk pati

90 atients with syncope of undetermined origin, ventricular tachyarrhythmias at electrophysiologic evalu

91 fibrosis on myocardial biopsy and history of ventricular tachyarrhythmias at presentation (P<0.05 for

92 from dogs that either did or did not exhibit ventricular tachyarrhythmias at the time of study were s

93 ility of using upstream therapies to abort a ventricular tachyarrhythmia before its onset.

94 art failure patients to an increased risk of ventricular tachyarrhythmias, but the incidence of cardi

95 The rate of sustained ventricular tachyarrhythmias by 3 months was 3% among pa

96 TEA reduced inducibility of ventricular tachyarrhythmias by 70%.

97 tients after termination of life-threatening ventricular tachyarrhythmias by an ICD.

98 enic focus in patients with life-threatening ventricular tachyarrhythmias can be curative.

99 Atrial and ventricular tachyarrhythmias can be perpetuated by up-re

100 ed ventricular tachycardia in whom sustained ventricular tachyarrhythmias cannot be induced have a si

101 spite their ability to effectively terminate ventricular tachyarrhythmias, cardiac mortality in patie

102 WTC attack, a total of 14 patients (11%) had ventricular tachyarrhythmias, compared with 5 (3.8%) in

103 modeling, and enhances the risk of malignant ventricular tachyarrhythmias complicating AVB.

104 Patients in whom sustained ventricular tachyarrhythmias could be induced were rando

105 on 29 patients from the Creighton University ventricular tachyarrhythmia database.

106 he ventricles are vulnerable to induction of ventricular tachyarrhythmia during delivery of atrial sh

107 ne phospholipids can induce lethal malignant ventricular tachyarrhythmias during acute cardiac ischem

108 None had complex ventricular tachyarrhythmias during EST.

109 he lack of complex polymorphic/bidirectional ventricular tachyarrhythmias during exercise stress test

110 survivors, 10/17 (59%) experienced sustained ventricular tachyarrhythmias during follow-up and 3 rece

111 The mean number of spontaneous nonsustained ventricular tachyarrhythmias during stage 2 and the occu

112 uring stage 2 and the occurrence of ischemic ventricular tachyarrhythmias during stage 3 also were si

113 in functional conduction block and reentrant ventricular tachyarrhythmias during the fixed drive asso

114 termine whether the occurrence of shocks for ventricular tachyarrhythmias during therapy with implant

115 Ventricular tachyarrhythmias eliciting shocks are often

116 ck efficacy was 83.0% for the first clinical ventricular tachyarrhythmia event; there were no differe

117 of atrial fibrillation (AF) in patients with ventricular tachyarrhythmias exist.

118 Premature stimulation induced ventricular tachyarrhythmia/fibrillation >60 seconds in

119 reduces the incidence of inducible sustained ventricular tachyarrhythmia/fibrillation in canine infar

120 1.6%) were treated by the WCD in response to ventricular tachyarrhythmia/fibrillation.

121 ia (VT) is a strong predictor of spontaneous ventricular tachyarrhythmia following ST-segment-elevati

122 ardiac arrest and arrhythmic death caused by ventricular tachyarrhythmias >/=240 per minute was obser

123 onths, conversion of spontaneously occurring ventricular tachyarrhythmias >200 bpm was identical (97.

124 ing conduction abnormalities, and atrial and ventricular tachyarrhythmias, guideline-directed diagnos

125 Ventricular tachyarrhythmias had a low positive and rela

126 Using more intervals to detect ventricular tachyarrhythmias has been associated with re

127 le cardioverter-defibrillator (ICD) to treat ventricular tachyarrhythmias have documented atrial tach

128 with a history of myocardial infarction and ventricular tachyarrhythmias have not been clearly defin

129 iac events (i.e., all-cause death, sustained ventricular tachyarrhythmia, hospitalization for heart f

130 1,993 consecutive patients presenting with ventricular tachyarrhythmias (i.e. ventricular tachycard

131 Giant cell myocarditis presented as nonfatal ventricular tachyarrhythmia in 10 patients and as a fata

132 Torsade de pointes ventricular tachyarrhythmia in the long QT syndrome is a

133 phase is characterized by propensity toward ventricular tachyarrhythmia in the setting of well-prese

134 er lifetime in 166 patients (19%), sustained ventricular tachyarrhythmias in 17 (2%), and permanent p

135 a uniform and pre-specified protocol induced ventricular tachyarrhythmias in 40% of patients: arrhyth

136 There was a total of 120 sustained ventricular tachyarrhythmias in 41 patients, of whom 54%

137 effectively suppressed catecholamine-induced ventricular tachyarrhythmias in Casq2-/- mice, whereas N

138 d stimulation (SCS) reduces the incidence of ventricular tachyarrhythmias in experimental models.

139 on at the ionic and molecular levels lead to ventricular tachyarrhythmias in HF are unknown.

140 digital 12-lead ECGs independently predicts ventricular tachyarrhythmias in ICD-eligible cardiomyopa

141 ventricular assist device (LVAD) therapy on ventricular tachyarrhythmias in patients with advanced c

142 lipidemia is associated with greater risk of ventricular tachyarrhythmias in patients with cardiovasc

143 an males, as well as resistance to inducible ventricular tachyarrhythmias in response to programmed e

144 alpha inhibition attenuated Ca(2+)-dependent ventricular tachyarrhythmias in TAB hearts challenged wi

145 the true frequency of subsequent spontaneous ventricular tachyarrhythmias in the absence of antiarrhy

146 intermediate LGE-SI is a better predictor of ventricular tachyarrhythmias (including nonsustained ven

147 reater likelihood and increased frequency of ventricular tachyarrhythmias (including NSVT) on ambulat

148 The incidence of ventricular tachyarrhythmia, including ventricular fibri

149 Ventricular tachyarrhythmia inducibility was assessed by

150 of case reports of R-on-T extrasystoles and ventricular tachyarrhythmia induction as a result of biv

151 well as effective shock delivery to convert ventricular tachyarrhythmia into sinus rhythm.

152 long QT syndrome associated with polymorphic ventricular tachyarrhythmia is emphasized.

153 Ventricular tachyarrhythmias long enough to cause implan

154 the trigger mechanisms of the initiation of ventricular tachyarrhythmias may be similar, irrespectiv

155 stimulation elicited infrequent monomorphic ventricular tachyarrhythmias (MVT), and dominant frequen

156 cardioverter-defibrillator interventions for ventricular tachyarrhythmias (n=31), resuscitated out-of

157 ts, most commonly with ICD interventions for ventricular tachyarrhythmias (n=33) or heart transplanta

158 Ventricular tachyarrhythmia occurred in 35% of the patie

159 After 90 days, no sustained ventricular tachyarrhythmia occurred in wearable cardiov

160 A total of 1100 episodes of spontaneous ventricular tachyarrhythmias occurred during a mean of 6

161 ion, ischemia, congestive heart failure, and ventricular tachyarrhythmias occurring during the index

162 tachycardia; and inducible, nonsuppressible ventricular tachyarrhythmia on electrophysiologic study

163 ent in 31% of patients presenting with index ventricular tachyarrhythmias on admission (70% paroxysma

164 Ventricular tachyarrhythmias on Holter electrocardiogram

165 iveness in preventing sudden death caused by ventricular tachyarrhythmia or fibrillation.

166 on-RV outflow tract) per 24 h; and symptoms, ventricular tachyarrhythmias, or attenuated blood pressu

167 d emergencies, including lack of response to ventricular tachyarrhythmias, pacing failure, and multip

168 ifference in the time to first recurrence of ventricular tachyarrhythmia (post hoc analysis) over the

169 Ventricular tachyarrhythmias present a unique set of sti

170 ocardial infarction who are at high risk for ventricular tachyarrhythmia, prophylactic therapy with a

171 cteristic ECG features preceding polymorphic ventricular tachyarrhythmias (PVTs).

172 nce of spontaneous and inducible polymorphic ventricular tachyarrhythmias (PVTs).

173 ty-three patients with recurrent hypotensive ventricular tachyarrhythmias refractory to lidocaine, pr

174 amiodarone is a relatively safe therapy for ventricular tachyarrhythmias refractory to other medicat

175 y of intravenous amiodarone in patients with ventricular tachyarrhythmias refractory to standard ther

176 associated higher risks for life-threatening ventricular tachyarrhythmias remain poorly understood.

177 Most patients with ventricular tachyarrhythmias resume driving early.

178 opulmonary resuscitation time and an initial ventricular tachyarrhythmia rhythm were associated with

179 The occurrence of ventricular tachyarrhythmias seems to follow circadian,

180 Twelve patients had ventricular tachyarrhythmias: seven had successful thera

181 to cardiac arrhythmias (atrial fibrillation, ventricular tachyarrhythmias, sudden cardiac death, and

182 s, which may underlie a circadian pattern of ventricular tachyarrhythmia/sudden cardiac death.

183 been assessed as predictors of death due to ventricular tachyarrhythmias/sudden death in patients wi

184 emodynamic benefits, CRT may also ameliorate ventricular tachyarrhythmia susceptibility in HF patient

185 resynchronization therapy's (CRT) impact on ventricular tachyarrhythmia susceptibility in patients w

186 a blinded manner (relative to date) for all ventricular tachyarrhythmias (tachycardia or fibrillatio

187 deceased patients to assess the incidence of ventricular tachyarrhythmias, the occurrence of shocks,

188 with allowing patients with life-threatening ventricular tachyarrhythmias to drive have not been quan

189 ive reports suggest a response of refractory ventricular tachyarrhythmias to intravenous amiodarone,

190 relation of ejection fraction and inducible ventricular tachyarrhythmias to mode of death in all 179

191 r each therapy, we reviewed 1238 episodes of ventricular tachyarrhythmias treated with shock therapy.

192 The occurrence of ventricular tachyarrhythmias triggering ICD therapy in t

193 Although ventricular tachyarrhythmias usually occur in the settin

194 he relationship between RWT and the risk for ventricular tachyarrhythmia (VA) in patients enrolled in

195 Programming of ventricular tachyarrhythmia (ventricular tachycardia [VT

196 r, the relationship between QRSd and risk of ventricular tachyarrhythmias (ventricular tachycardia/ve

197 aventricular conduction delay, and malignant ventricular tachyarrhythmias (ventricular tachycardia/ve

198 A total of 34 ventricular tachyarrhythmia/ventricular fibrillation epi

199 ferences were observed irrespective of index ventricular tachyarrhythmia (VT or VF), LV dysfunction o

200 occurrence of complete heart block (CHB) and ventricular tachyarrhythmia (VT) after ASA to better und

201 Spontaneous ventricular tachyarrhythmia (VT)/ventricular fibrillatio

202 d catheter ablation (CA) in the treatment of ventricular tachyarrhythmias (VT) in patients with an IC

203 Spontaneous ventricular tachyarrhythmias (VT) occurred in more than

204 structural heart disease (SHD) and recurrent ventricular tachyarrhythmias (VT).

205 imation of the risk of life-threatening (LT) ventricular tachyarrhythmia (VTA) in patients with LMNA

206 Outcome measures included ventricular tachyarrhythmia (VTA), atrial tachyarrhythmi

207 etween TWA and the spontaneous initiation of ventricular tachyarrhythmias (VTA) in humans are unknown

208 d predict the onset of spontaneous sustained ventricular tachyarrhythmias (VTAs) better than previous

209 arly repolarization (ER) characteristics and ventricular tachyarrhythmias (VTAs) in patients with acu

210 the outcomes of heart failure (HF) or death, ventricular tachyarrhythmias (VTAs), and death.

211 eference], 36%-50%, and >50%) on outcomes of ventricular tachyarrhythmias (VTAs), VTA >/=200 bpm, ICD

212 ion therapy (CRT) and the risk of subsequent ventricular tachyarrhythmias (VTAs).

213 can result in Ca(2+) waves, a major cause of ventricular tachyarrhythmias (VTs) and sudden death.

214 Ws, triggered activities, and stress-induced ventricular tachyarrhythmias (VTs) in a mouse model of c

215 r more short-long (S-L) cardiac sequences to ventricular tachyarrhythmias (VTs) in the long QT syndro

216 s associated with an enhanced propensity for ventricular tachyarrhythmias (VTs) under conditions of m

217 rocardiograms and development of spontaneous ventricular tachyarrhythmias (VTs), seizures, and sudden

218 larization and the occurrence of polymorphic ventricular tachyarrhythmias (VTs), sometimes with a twi

219 to AP-A that developed LQTS and polymorphic ventricular tachyarrhythmias (VTs).

220 Ventricular tachyarrhythmia was induced 122 times: 2 of

221 in whom postcollapse rhythm was evaluated, a ventricular tachyarrhythmia was observed in 9.

222 s to save 1 patient with abolition of lethal ventricular tachyarrhythmias was 6:1, similar to randomi

223 First shock efficacy for ventricular tachyarrhythmias was high regardless of base

224 ejection fraction, atrial fibrillation, and ventricular tachyarrhythmias) was also executed.

225 No episodes of ventricular tachyarrhythmia were induced by atrial shock

226 old knockout mice, spontaneous and inducible ventricular tachyarrhythmias were common, occurring in 6

227 hort, ICD interventions for life-threatening ventricular tachyarrhythmias were frequent and highly ef

228 D interventions terminating life-threatening ventricular tachyarrhythmias were frequent.

229 Patients in whom sustained ventricular tachyarrhythmias were induced by programmed

230 tor implantation, but appropriate shocks for ventricular tachyarrhythmias were noted only in a minori

231 Until Day 90, sustained ventricular tachyarrhythmias were observed in 24 wearabl

232 al of 704 patients with inducible, sustained ventricular tachyarrhythmias were randomly assigned to t

233 re than 500 ms (an indicator of potential of ventricular tachyarrhythmia) were reported.

234 e electrophysiologic mechanism of atrial and ventricular tachyarrhythmias, whether they are sustained

235 Four episodes were incorrectly classified as ventricular tachyarrhythmia, which led to inappropriate

236 Ventricular tachyarrhythmias, which are difficult to ind

237 ts in the past 3 decades in the treatment of ventricular tachyarrhythmias with device-based therapy,

238 More than one third of the patients had a ventricular tachyarrhythmia within the last hour of life

239 of protein in wild-type mice), and malignant ventricular tachyarrhythmias within minutes of ischemia.

240 r ICD therapy reduced sudden death caused by ventricular tachyarrhythmias without affecting heart fai